应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
NVAX 诺瓦瓦克斯医药
盘后交易 08-26 17:56:14 EDT
9.21
-0.23
-2.44%
盘后
9.24
+0.03
+0.33%
17:55 EDT
最高
9.44
最低
9.13
成交量
350.76万
今开
9.33
昨收
9.44
日振幅
3.28%
总市值
15.14亿
流通市值
13.17亿
总股本
1.64亿
成交额
3,244万
换手率
2.45%
流通股本
1.43亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Moderna与默克皮肤癌疫苗晚期试验成功，BioNTech美股大涨17%，诺瓦瓦克斯医药上涨4.5%
美股速递 · 08-19
Moderna与默克皮肤癌疫苗晚期试验成功，BioNTech美股大涨17%，诺瓦瓦克斯医药上涨4.5%
美股开盘 | 三大指数高开，Moderna涨超84%，迈威尔科技涨超10%
老虎资讯综合 · 08-19
美股开盘 | 三大指数高开，Moderna涨超84%，迈威尔科技涨超10%
生物科技个股盘前大涨，因莫德纳与默沙东联合研发的黑色素瘤疫苗大型临床试验取得成功。拜恩泰科的美股上涨17.4%，诺瓦瓦克
智通财经 · 08-19
生物科技个股盘前大涨，因莫德纳与默沙东联合研发的黑色素瘤疫苗大型临床试验取得成功。拜恩泰科的美股上涨17.4%，诺瓦瓦克
诺瓦瓦克斯医药：Nuvaxovid生产技术转移至赛诺菲预计2027年中完成，将触发7500万美元里程碑付款
美股速递 · 08-06
诺瓦瓦克斯医药：Nuvaxovid生产技术转移至赛诺菲预计2027年中完成，将触发7500万美元里程碑付款
诺瓦瓦克斯医药Q2调整后EPS为2.51美元 高于预期
格隆汇 · 08-06
诺瓦瓦克斯医药Q2调整后EPS为2.51美元 高于预期
财报前瞻｜诺瓦瓦克斯医药本季度营收预计下降65.47%，机构观点偏看多
财报Agent · 07-31
财报前瞻｜诺瓦瓦克斯医药本季度营收预计下降65.47%，机构观点偏看多
美股疫苗概念股逆势上涨！Moderna涨超7%，诺瓦瓦克斯医药涨近6%
老虎资讯综合 · 06-23
美股疫苗概念股逆势上涨！Moderna涨超7%，诺瓦瓦克斯医药涨近6%
Mabion签署协议附件，将诺瓦瓦克斯医药的生产协议延长至2029年底
投资观察 · 06-18
Mabion签署协议附件，将诺瓦瓦克斯医药的生产协议延长至2029年底
美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点
美股速递 · 05-29
美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点
赛诺菲宣布将Xfg蛋白Nuvaxovid疫苗作为其2026-27年度全球唯一新冠产品进行生产
美股速递 · 05-28
赛诺菲宣布将Xfg蛋白Nuvaxovid疫苗作为其2026-27年度全球唯一新冠产品进行生产
异动解读 | FDA探讨更新新冠疫苗针对XFG变异株，诺瓦瓦克斯医药盘中大涨12.54%
异动解读 · 05-26
异动解读 | FDA探讨更新新冠疫苗针对XFG变异株，诺瓦瓦克斯医药盘中大涨12.54%
Shah资本管理：坚信第二季度需回购1000万至2000万股诺瓦瓦克斯股票，以彰显对其科学与战略的信心并缓解历史稀释影响
美股速递 · 05-15
Shah资本管理：坚信第二季度需回购1000万至2000万股诺瓦瓦克斯股票，以彰显对其科学与战略的信心并缓解历史稀释影响
Shah资本管理：新冠/流感联合疫苗三期试验须即刻启动，或借力赛诺菲，或依托诺瓦瓦克斯自身（创新合作模式）
美股速递 · 05-15
Shah资本管理：新冠/流感联合疫苗三期试验须即刻启动，或借力赛诺菲，或依托诺瓦瓦克斯自身（创新合作模式）
Shah资本管理：坚信诺瓦瓦克斯医药须在2026年实现盈利，需进一步削减包括SG&A和研发在内的开支——转向以AI为核心的运营
美股速递 · 05-15
Shah资本管理：坚信诺瓦瓦克斯医药须在2026年实现盈利，需进一步削减包括SG&A和研发在内的开支——转向以AI为核心的运营
沙资本管理公司于2026年5月14日向诺瓦瓦克斯医药董事会提交演示文稿
美股速递 · 05-15
沙资本管理公司于2026年5月14日向诺瓦瓦克斯医药董事会提交演示文稿
Shah资本管理：将在诺瓦瓦克斯医药6月18日股东会投票中，对五项提案均投反对票——SEC文件披露
美股速递 · 05-15
Shah资本管理：将在诺瓦瓦克斯医药6月18日股东会投票中，对五项提案均投反对票——SEC文件披露
异动解读 | 疫苗板块受莫德纳利好消息带动，诺瓦瓦克斯医药盘前大涨5.34%
异动解读 · 05-11
异动解读 | 疫苗板块受莫德纳利好消息带动，诺瓦瓦克斯医药盘前大涨5.34%
异动解读 | 诺瓦瓦克斯医药盘中大涨17.96%，因第一季度营收远超预期
异动解读 · 05-07
异动解读 | 诺瓦瓦克斯医药盘中大涨17.96%，因第一季度营收远超预期
异动解读 | 股东敦促资本管理，诺瓦瓦克斯医药盘前大涨7.64%
异动解读 · 04-08
异动解读 | 股东敦促资本管理，诺瓦瓦克斯医药盘前大涨7.64%
诺瓦瓦克斯医药盘前股价飙升6.1%；维权投资者Shah Capital宣布将投票反对公司高管薪酬及董事提名
美股速递 · 04-08
诺瓦瓦克斯医药盘前股价飙升6.1%；维权投资者Shah Capital宣布将投票反对公司高管薪酬及董事提名
公司概况
公司名称：
诺瓦瓦克斯医药
所属市场：
NASDAQ
上市日期：
--
主营业务：
Novavax, Inc.于1987年根据美国特拉华州法律注册成立，是一家临床阶段的生物制药公司，专注于重组纳米颗粒疫苗和佐剂的发现、开发和商业化。该公司的疫苗技术平台基于包括病毒样颗粒（VLP）和蛋白质纳米颗粒候选疫苗的专有重组纳米颗粒疫苗技术。该公司的候选疫苗是基因工程的三维纳米结构，其中包含了免疫学上重要的蛋白质。公司的疫苗产品管线针对多种传染病，候选药物目前处于呼吸道合胞病毒（RSV）、季节性流感、大流行性流感的临床开发阶段。此外，该公司在印度的合资公司CPL Biologics Private Limited（CPLB）正在积极开发多款候选疫苗，这些候选疫苗由诺瓦瓦克斯医药进行基因工程改造。
发行价格：
--
{"stockData":{"symbol":"NVAX","market":"US","secType":"STK","nameCN":"诺瓦瓦克斯医药","latestPrice":9.21,"timestamp":1787774400000,"preClose":9.44,"halted":0,"volume":3507619,"hourTrading":{"tag":"盘后","latestPrice":9.24,"preClose":9.21,"latestTime":"17:55 EDT","volume":9540,"amount":87926.09688,"timestamp":1787781344056,"change":0.03,"changeRate":0.003257,"amplitude":0.011944},"delay":0,"changeRate":-0.024364406779660876,"floatShares":143000000,"shares":164427429,"eps":-1.518069,"marketStatus":"盘后交易","change":-0.23,"latestTime":"08-26 17:56:14 EDT","open":9.33,"high":9.44,"low":9.13,"amount":32443693.879548,"amplitude":0.032839,"askPrice":9.25,"askSize":464,"bidPrice":9.1,"bidSize":250,"shortable":3,"etf":0,"ttmEps":-1.518069,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.44,"preHourTrading":{"tag":"盘前","latestPrice":9.34,"preClose":9.44,"latestTime":"09:27 EDT","volume":12154,"amount":113976.833188,"timestamp":1787750838889,"change":-0.1,"changeRate":-0.010593,"amplitude":0.024163},"postHourTrading":{"tag":"盘后","latestPrice":9.24,"preClose":9.21,"latestTime":"17:55 EDT","volume":9540,"amount":87926.09688,"timestamp":1787781344056,"change":0.03,"changeRate":0.003257,"amplitude":0.011944},"volumeRatio":0.432371,"optionData":{"bulkOrders":[{"symbol":"NVAX","call":false,"expireDate":1799989200000,"strike":"10.0","timestamp":1787760381270,"price":2.11,"volume":14409,"amount":3040299,"type":"+"},{"symbol":"NVAX","call":false,"expireDate":1832043600000,"strike":"10.0","timestamp":1787760381270,"price":3.41,"volume":14409,"amount":4913469,"type":"-"}]},"impliedVol":0.7352,"impliedVolPercentile":0.1673},"requestUrl":"/m/hq/s/NVAX/wiki","defaultTab":"wiki","newsList":[{"id":"1175493233","title":"Moderna与默克皮肤癌疫苗晚期试验成功，BioNTech美股大涨17%，诺瓦瓦克斯医药上涨4.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175493233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175493233?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:40","pubTimestamp":1787146808,"startTime":"0","endTime":"0","summary":"Moderna与默克联合开发的皮肤癌疫苗在晚期临床试验中大获成功，这一消息引发市场连锁反应。BioNTech在美国上市的股票价格应声上涨17%，而诺瓦瓦克斯医药（Novavax）股价亦攀升4.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","BK4585","NVAX","BK4139","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162002657","title":"美股开盘 | 三大指数高开，Moderna涨超84%，迈威尔科技涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162002657","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162002657?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:30","pubTimestamp":1787146228,"startTime":"0","endTime":"0","summary":"8月19日，美股三大指数集体高开，道琼斯指数涨0.37%，标普500指数涨0.41%，纳斯达克综合指数涨0.36%。Moderna涨超84%，mRNA癌症疫苗三期试验成功，黑色素瘤治疗迎来历史性突破。医药股大涨，BioNTech SE涨超17%，默沙东涨超8%，诺瓦瓦克斯医药涨超6%。SK海力士涨近5%。公司拟回购40万亿韩元并注销。迈威尔科技涨超10%。消息面上，公司表示已向谷歌发行最多5897万股认股权证，行权价格设定为每股206.58美元。NEBIUS跌超6%，公司拟发行45亿美元可转换优先票据。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXL","MRNX","GNOM","IHE","SG9999002224.SGD","LU1814569148.SGD","LU1720051108.HKD","LU0965509101.SGD","BNTX","LU1720051017.SGD","BK4532","LU1023059063.AUD","BK4551","SKHX","LU2244417387.USD","LU1066053197.SGD","LU0476273544.USD","LU2092937148.SGD","BK4516","LU0210528500.USD","LU0965508806.USD","BK4527","LU2272731600.USD","NBIL","LU1119994496.HKD","BK4612","IYH","BK4534","TRUC","LU0348723411.USD","LU2543165471.USD","LU1983299246.USD","IE00BYQQ9H92.USD","MRVU","BK4141","IE0004091025.USD","LU0130102774.USD","LU2265009873.SGD","LU0950373646.USD","LU1066051225.USD","BK4507","LU2272731782.SGD","LGHT","BK4535","LU1261432733.SGD","LU2491050071.SGD","IE00BWXC8680.SGD","IE00BMPRXQ63.HKD","LU0130517989.USD","IE00BFTCPJ56.SGD","BK4514","LU2237443978.SGD","LU1093756325.SGD","LU0203347892.USD","IE00BMPRXR70.SGD","LU0079474960.USD","LU0274383776.USD","ARTY","IE0004445239.USD","BK4587","LU1074936037.SGD","LU0648001328.SGD","NBIG","LU2463028550.USD","LU0868494708.USD","IE00BJLML261.HKD","LU2360107168.USD","SKHA","LU2458330169.SGD","LU1674673691.USD","IE00BJJMRZ35.SGD","LU0494093205.USD","LU1116320901.HKD","IE00B1BXHZ80.USD","LU2720916845.USD","LU2357627491.SGD","LU2106854487.HKD","UDOW","LU1839511570.USD","LU1280957306.USD","LU2125909593.SGD","IE00B1XK9C88.USD","SG9999018857.SGD","LU1803068979.SGD","LU0323591593.USD","DIA","LU1934455863.HKD","LU0162691827.USD","LU1046421795.USD","LU1989772923.USD","LU0689626769.HKD","LU2322448957.HKD","PAWZ","SG9999001077.SGD","LU0320765489.SGD","SG9999018865.SGD","GTEK","QQQA","IE0004086264.USD","LU0466842654.USD","LU1316542783.SGD","LU2133065610.SGD","AIFD","07709","SG9999015986.USD","IE0000B7K699.USD","SOXY","AIS","LU2023250504.SGD","LU1642822529.SGD","BK4605","LU1066051811.HKD","GOOP","LU0788109477.HKD","SGOOGmain","LU1923622614.USD","SG9999002232.USD","BK4585","DDM","SNPE","LU0642271901.SGD","BK4559","LU2764263039.SGD","SKUU","IE0002141913.USD","LU0878866978.SGD","LU0823421333.USD","DOG","SGXZ80539844.SGD","LU0444973449.USD","BK4077","IE00B5TLWC47.USD","LU1992135399.USD","LU2077746001.SGD","LU2290526834.HKD","LU0965509010.AUD","IE000BZT7R73.USD","LU1852331112.SGD","GOOG","SKDD","LU1169589451.USD","LU0081259029.USD","LU2931357623.SGD","LU1585245621.USD","BK4548","IE00BJJMRX11.SGD","IE00B5949003.HKD","LU2237443382.USD","LU0211331839.USD","LU0823431647.USD","LU0061475181.USD","LU1066051498.USD","LU0122379950.USD","IE00BJJMRY28.SGD","IE000WAW04H5.SGD","IE0034235303.USD","LU1169590202.USD","IE00B2B36J28.USD","LU2637965513.SGD","LU2552382058.USD","LU2092627202.USD","LU0265550359.USD","HRTS","IE00B3S45H60.SGD","IXJ","LU1127390331.HKD","LU0070302665.USD","LU0289941410.SGD","SDOW","IE00BFSS8Q28.SGD","IE00B4R5TH58.HKD","NEBX","MRNY","LU1201861249.SGD","XLV","SG9999014567.USD","LU0053666078.USD","LU1235294995.USD","BK4007","WDNA","LU0320765646.SGD","LU0072462426.USD","LU0477156953.USD","LU2125154935.USD","LU0942090050.USD","BK4547","LU2357305700.SGD","BK4553","SMHX","IE00B775H168.HKD","LU1037948897.HKD","WUGI","LU1035775433.USD","JDOC","SG9999014914.USD","LU1035773651.USD","LU2089985449.USD","LU2089984988.USD","LU2237443622.USD","FTXL","NBIZ","IE00BK4W5L77.USD","LU0329931173.USD","LU2468319806.SGD","LU1699723380.USD","LU2098885051.SGD","LU0859254822.USD","FTXH","SG9999015341.SGD","SK","LU2286300806.USD","LU0170899867.USD","LU2764263203.CNY","LU2361044949.HKD","IE000MB6IJN5.SGD","GOOX","LU1989771016.USD","LU2112291526.USD","BK4581","BK4568","MRK","LU0175139822.USD","FHLC","LU0203345920.USD","GXPC","SG9999014898.SGD","LU1069347547.HKD","LU0234570918.USD","FDTX","BMED","LU0056508442.USD","LU1691799644.USD","BK4604","LU0444971666.USD","LU0724617625.USD","DXD","BK4525","LU1037948541.HKD","LU1941712264.USD","USJW.SI","VHT","LU0329931090.USD","LU0308772762.SGD","LU2125154778.USD","IE00BJT1NW94.SGD","LU1571399168.USD","BK4550","LU0289960550.SGD","LU2087621335.USD","IDNA","LU0127658192.USD","LU1084165304.USD","LU1815336760.USD","SG9999015952.SGD","NBIS","LU1992135472.HKD","LU0823434583.USD","LU2237443465.HKD","SG9999013999.USD","BK4543","LU1069344957.HKD","LU0203201768.USD","JGRO","SKHYV","YMmain","SG9999014542.SGD","IE00BLSP4239.USD","LU0531971165.HKD","LU2237443549.SGD","LU2487616109.SGD","SG9999014880.SGD","IE000M9KFDE8.USD","LU1303367103.USD","SG9999015978.USD","LU0719512351.SGD","SGXZ57979304.SGD","LU1861215975.USD","SG9999001176.SGD","LU2433249047.HKD","LU2458330243.SGD","LU0082616367.USD","LU0456855351.SGD","LU2602419157.SGD","LU0106261372.USD","IE0004445015.USD","LU1674673428.USD","LU1489326972.SGD","LU2247934214.USD","LU1778281490.HKD","BK4602","LU2896262040.SGD","IE00BLSP4452.SGD","IE000SO60NU8.SGD","LU0238689110.USD","LU0124676726.USD","LU0006306889.USD","LU0068578508.USD","SG9999000418.SGD","LU0433182093.SGD","LU1989764748.USD","LU1934455194.USD","MRVL","LU2108987350.USD","LU1917777945.USD","XNTK","LU1804176565.USD","BK4515","LU1430594728.SGD","IE0009355771.USD","LU0957808578.USD","MRNA","SKHU","BK4588","IE00BFXG0V08.USD","SKHY","LU2491050154.USD","LU1989764664.SGD","EFIV","SG9999014575.USD","LU1291159041.SGD","LU1093756168.USD","LU1861220033.SGD","MRVX","VOX","LU0098860793.USD","LU0640476718.USD","LU0889565833.HKD","LU1989772840.SGD","LU0985489474.SGD","LU2324357040.USD","LU0823434740.USD","LU0432979614.USD","LU1823568750.SGD","SG9999001440.SGD","IE00B775SV38.USD","IE00BN29S564.USD","LU0154236417.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU1929549753.HKD","IE00BK4W5M84.HKD","MVLL","LU1548497426.USD","PPH","LU1974910355.USD","LU0234572021.USD","LU0210536198.USD","BK4533","SGXZ31699556.SGD","LU2023250843.SGD","LU0266013472.USD","LTL","IE00BFSS7M15.SGD","BK4579","LU0823431563.USD","LU2461242641.AUD","NVAX","LU0868494617.USD","XLC","BK4139","LU0861579265.USD",".DJI","IE00BSNM7G36.USD","LU1934455277.USD","LU1979441026.SGD","SG9999015358.SGD","FAI","LU0109392836.USD","LU2361045086.USD","LU2552382215.SGD","LU0203202063.USD","LU2452424414.USD","IE00BZ199S13.USD","LU0058720904.USD","LU2360032135.SGD","LU2322448791.USD","LU1941712348.USD","LU0208291251.USD","LU0980610538.SGD","LU0965509283.SGD","IE0009356076.USD","BK4592","LU2552382132.HKD","SG9999015945.SGD","LU0289739699.SGD","LU1914381329.SGD","BK4609","IE0005OL40V9.USD","LU2237443895.HKD","IE00B4JS1V06.HKD","LU2272731865.HKD","SKHZ","LU0985320562.USD","IE00B7KXQ091.USD","BK4501","LU1061106388.HKD","LU2125909247.SGD","LU0187121727.USD","LU0072461881.USD","LU1116320737.USD","LU2764262908.HKD","DTCR","IE00BKDWB100.SGD","LU2491049909.HKD","LU1162221912.USD","BK4554","BK4097","LU0786609619.USD","SG9999014559.SGD","LU0823416689.USD","IE000F7OJYX1.SGD","HYNX","RXL","LU0265550946.USD","LU2473716301.USD","BK4566","SG9999001176.USD","LU0133085943.USD","FCOM","LU2361044865.SGD","SG9999014906.USD","GDOC","LU0823421416.USD","CNEQ","IE00BMPRXN33.USD","TRUH","SG9999017495.SGD","IE00BN8TJ469.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660942332","title":"生物科技个股盘前大涨，因莫德纳与默沙东联合研发的黑色素瘤疫苗大型临床试验取得成功。拜恩泰科的美股上涨17.4%，诺瓦瓦克","url":"https://stock-news.laohu8.com/highlight/detail?id=2660942332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660942332?lang=zh_cn&edition=full","pubTime":"2026-08-19 20:32","pubTimestamp":1787142755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2491050154.USD","LU1430594728.SGD","BK4533","LU2106854487.HKD","LU2360032135.SGD","FHLC","SG9999014567.USD","LU1974910355.USD","LU0106261372.USD","BK4534","BNTX","LU0980610538.SGD","LU0006306889.USD","LU2125909247.SGD","LU2361045086.USD","SG9999001176.SGD","SG9999013999.USD","LU0965509283.SGD","LU1699723380.USD","SG9999001176.USD","LU0208291251.USD","LU1923622614.USD","LU0211331839.USD","LU1934455863.HKD","BK4535","LU1069347547.HKD","SG9999015341.SGD","LU1934455277.USD","LU0130517989.USD","LU1037948897.HKD","SG9999014542.SGD","LU1066051225.USD","LU1585245621.USD","IYH","LU0859254822.USD","RXL","LU1917777945.USD","LU0965509010.AUD","SG9999002224.SGD","LU2112291526.USD","LU1035773651.USD","LU1066051811.HKD","IHE","IXJ","LU0058720904.USD","LU1941712264.USD","SGXZ57979304.SGD","LU0098860793.USD","LU2023250843.SGD","LU1061106388.HKD","VHT","IE000M9KFDE8.USD","BK4139","LU0130102774.USD","LU2468319806.SGD","MRK","LU0985320562.USD","LU0265550359.USD","IE00BLSP4452.SGD","LU1057294990.SGD","LU0868494617.USD","IE00BN8TJ469.HKD","FTXH","SG9999002232.USD","HRTS","LU1941712348.USD","LU1989772840.SGD","BK4585","LU0861579265.USD","LU0234572021.USD","LU1989772923.USD","BK4588","IE0009355771.USD","LU0203345920.USD","BK4547","LU2357627491.SGD","LU2125154778.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","IE00BLSP4239.USD","SG9999014559.SGD","BK4516","LU0122379950.USD","SG9999001440.SGD","LU0203347892.USD","LU1037948541.HKD","LU0238689110.USD","LU1201861249.SGD","LU0266013472.USD","LU2461242641.AUD","LU0289739699.SGD","LU1093756168.USD","LU2491049909.HKD","LU2125909593.SGD","LU0648001328.SGD","LU2361044865.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU1116320737.USD","LU1066053197.SGD","LU1571399168.USD","LU1116320901.HKD","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4548","LU1929549753.HKD","LU1989771016.USD","PPH","LU2324357040.USD","LU2361044949.HKD","IE00B1BXHZ80.USD","JDOC","XLV","LU0265550946.USD","LU0868494708.USD","LU2023250504.SGD","BK4559","LU1162221912.USD","LU1983299246.USD","LU0823416689.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","TRUH","LU0124676726.USD","LU0432979614.USD","LU0070302665.USD","SG9999015358.SGD","LU0965508806.USD","LU2089984988.USD","BK4550","NVAX","LU1093756325.SGD","BK4007","LU2125154935.USD","BK4551","LU0320765646.SGD","IE00BJJMRZ35.SGD","LU2433249047.HKD","LU1066051498.USD","IE00BFTCPJ56.SGD","LU0942090050.USD","PAWZ","SG9999014575.USD","LU0477156953.USD","LU2491050071.SGD","LU0965509101.SGD","LU1934455194.USD","LU0689626769.HKD","LU0320765489.SGD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181888910","title":"诺瓦瓦克斯医药：Nuvaxovid生产技术转移至赛诺菲预计2027年中完成，将触发7500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1181888910","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181888910?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:05","pubTimestamp":1786017933,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（Novavax）宣布，其新冠疫苗Nuvaxovid的生产技术向赛诺菲（Sanofi）的转移工作预计将在2027年年中收官。这一里程碑式的进展，将为该公司带来一笔高达7500万美元的付款。技术的交接与转移，不仅是双方合作深化的标志，更预示着诺瓦瓦克斯未来现金流的一次重要提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NVAX","BK4568","BK4547","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657263538","title":"诺瓦瓦克斯医药Q2调整后EPS为2.51美元 高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657263538","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657263538?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:34","pubTimestamp":1786016088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["UUP","BK4588","BK4547","BK4139","NVAX","BK4568","BK4585","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138089174","title":"财报前瞻｜诺瓦瓦克斯医药本季度营收预计下降65.47%，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1138089174","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138089174?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:15","pubTimestamp":1785442541,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药将于2026年08月06日盘前公布最新季度业绩，市场预期本季收入与利润承压，关注授权里程碑与费用收缩进展。一致预期显示，本季度诺瓦瓦克斯医药收入预计为5,109.83万美元，同比下降65.47%；调整后每股收益预计为-0.41美元，同比下降385.71%；息税前利润预计为-6,853.67万美元，同比下降1,256.06%。上季诺瓦瓦克斯医药实现收入1.40亿美元，同比下降79.07%；毛利率19.42%；归属于母公司股东的净利润为-949.10万美元，净利率-6.80%；调整后每股收益为-0.06美元，同比下降102.05%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜诺瓦瓦克斯医药本季度营收预计下降65.47%，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172051486","title":"美股疫苗概念股逆势上涨！Moderna涨超7%，诺瓦瓦克斯医药涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172051486","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172051486?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:25","pubTimestamp":1782224710,"startTime":"0","endTime":"0","summary":"6月23日，美股疫苗概念股逆势上涨，$Moderna(MRNA)$涨超7%，$诺瓦瓦克斯医药(NVAX)$涨近6%，$阿斯利康(AZN)$、$葛兰素史克(GSK)$、$强生(JNJ)$均涨超2%。","market":"us","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","NVAX","159646","BK4588","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187566594","title":"Mabion签署协议附件，将诺瓦瓦克斯医药的生产协议延长至2029年底","url":"https://stock-news.laohu8.com/highlight/detail?id=1187566594","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187566594?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:31","pubTimestamp":1781767891,"startTime":"0","endTime":"0","summary":"6月18日——Mabion SA宣布，其已与诺瓦瓦克斯医药签署了一份生产协议的附件。根据该附件，双方现有的生产合作协议将延长至2029年年底。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4547","BK4139","BK4568","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139235440","title":"美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1139235440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139235440?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:28","pubTimestamp":1779992883,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的疫苗顾问小组已投票支持一项建议，即在2026-2027年度的新冠疫苗接种活动中，应将疫苗的靶点更新为当前流行的Jn.1谱系Xfg变异株。这一决定标志着公共卫生机构在应对病毒持续演变方面迈出了关键一步。相关企业可能需要据此调整其疫苗成分，以符合新的公共卫生指导。随着病毒变异，疫苗的定期更新已成为新常态，以确保其防护效力。最终决定权仍在FDA，但通常其会采纳顾问委员会的建议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","IE000M9KFDE8.USD","BK4585","IE0002270589.USD","BK4547","SG9999001176.USD","BK4551","BK4532","IE00B3T34201.USD","MRNX","SGXZ57979304.SGD","LU0058720904.USD","SG9999002224.SGD","LU0234572021.USD","LU1894683348.USD","LU0170899867.USD","LU0306806265.USD","IE00B19Z3581.USD","BK4592","MRNY","LU1066051498.USD","IE00BBT3K403.USD","SG9999002232.USD","PFE","SG9999013999.USD","LU0321505868.SGD","LU1894683264.USD","BK4534","IE00BLSP4452.SGD","LU0122379950.USD","BK4533","BK4588","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0225771236.USD","LU0868494617.USD","MRNA","BK4501","LU0456855351.SGD","BK4581","LU0225284248.USD","LU0289739699.SGD","LU0306807586.USD","SG9999001176.SGD","LU1057294990.SGD","LU1883839398.USD","SG9999011175.SGD","LU0985481810.HKD","BK4007","BK4139","BK4550","BK4568","IE00BLSP4239.USD","BK4599","BK4548","NVAX","LU1023059063.AUD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129861349","title":"赛诺菲宣布将Xfg蛋白Nuvaxovid疫苗作为其2026-27年度全球唯一新冠产品进行生产","url":"https://stock-news.laohu8.com/highlight/detail?id=1129861349","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129861349?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:21","pubTimestamp":1779970899,"startTime":"0","endTime":"0","summary":"赛诺菲在简报文件中表示，已确定将Xfg蛋白Nuvaxovid疫苗作为公司在2026-27年度全球范围内唯一的新冠疫苗产品进行生产制造。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NVAX","BK4588","BK4568","BK4139","BK4585","GCVRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195543647","title":"异动解读 | FDA探讨更新新冠疫苗针对XFG变异株，诺瓦瓦克斯医药盘中大涨12.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195543647","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195543647?lang=zh_cn&edition=full","pubTime":"2026-05-26 23:35","pubTimestamp":1779809715,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘中大涨12.54%，引起了市场的广泛关注。消息面上，美国食品药品监督管理局(FDA)顾问委员会将讨论是否应在2026-27年度的免疫接种活动中，对新冠疫苗进行更新，以针对目前流行的XFG亚型变异株。FDA表示，疫苗制造商已表示准备为2026-27年度的疫苗接种季生产XFG疫苗。目前美国已批准三种新冠疫苗使用，其中包括诺瓦瓦克斯的蛋白疫苗。诺瓦瓦克斯已于2024年将新冠疫苗授权给法国制药商赛诺菲，该交易价值至少12亿美元。市场预期，若FDA决定更新疫苗配方，诺瓦瓦克斯作为重要的疫苗供应商之一，可能从中获得新的商业机会，从而推动了股价的显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157177942","title":"Shah资本管理：坚信第二季度需回购1000万至2000万股诺瓦瓦克斯股票，以彰显对其科学与战略的信心并缓解历史稀释影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1157177942","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157177942?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:23","pubTimestamp":1778847798,"startTime":"0","endTime":"0","summary":"Shah资本管理公司强调，诺瓦瓦克斯医药（NVAX）必须在今年第二季度进行规模在1000万至2000万股之间的股票回购。此举被视为管理层对公司核心科学实力与长期发展战略投下坚定信心票的关键行动。同时，该回购计划旨在积极应对并缓解因过往融资活动所带来的股权稀释效应，从而向市场传递更为明确的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4568","BK4139","BK4588","BK4585","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126402163","title":"Shah资本管理：新冠/流感联合疫苗三期试验须即刻启动，或借力赛诺菲，或依托诺瓦瓦克斯自身（创新合作模式）","url":"https://stock-news.laohu8.com/highlight/detail?id=1126402163","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126402163?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:23","pubTimestamp":1778847797,"startTime":"0","endTime":"0","summary":"Shah资本管理公司强调，针对新冠与流感的联合疫苗，其关键性的第三阶段临床试验必须立即启动。可行的路径包括通过赛诺菲进行合作，或由诺瓦瓦克斯医药自身主导并寻求创新性的合作伙伴关系。该公司认为，此举对于推进该重要疫苗的研发进程至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NVAX","BK4568","BK4139","BK4547","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197343258","title":"Shah资本管理：坚信诺瓦瓦克斯医药须在2026年实现盈利，需进一步削减包括SG&A和研发在内的开支——转向以AI为核心的运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1197343258","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197343258?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:22","pubTimestamp":1778847739,"startTime":"0","endTime":"0","summary":"Shah资本管理公司近期发表观点，坚信诺瓦瓦克斯医药必须在2026年实现盈利。为实现这一目标，该公司认为诺瓦瓦克斯需要进一步削减运营支出，范围涵盖销售、一般及行政管理费用（SG&A）以及研发投入。关键在于，这些成本削减措施应伴随着运营模式的根本性转变，即向以人工智能为核心的高效运营体系迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4588","BK4547","BK4585","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123475443","title":"沙资本管理公司于2026年5月14日向诺瓦瓦克斯医药董事会提交演示文稿","url":"https://stock-news.laohu8.com/highlight/detail?id=1123475443","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123475443?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:20","pubTimestamp":1778847637,"startTime":"0","endTime":"0","summary":"2026年5月14日，沙资本管理公司向诺瓦瓦克斯医药（Novavax）董事会提交了一份演示文稿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4547","NVAX","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194485217","title":"Shah资本管理：将在诺瓦瓦克斯医药6月18日股东会投票中，对五项提案均投反对票——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1194485217","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194485217?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:20","pubTimestamp":1778847619,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，投资机构Shah资本管理公司表示，将在诺瓦瓦克斯医药于6月18日举行的股东投票中，对全部五项提案投出反对票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4568","BK4139","BK4588","BK4585","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166301205","title":"异动解读 | 疫苗板块受莫德纳利好消息带动，诺瓦瓦克斯医药盘前大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166301205","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166301205?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:29","pubTimestamp":1778506189,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘前股价大涨5.34%，引起了市场的广泛关注。消息面上，疫苗制造商莫德纳(MRNA)宣布与美国陆军传染病医学研究所合作，针对汉坦病毒开展了临床前研究，并且已与高丽大学签署研究协议，在其mRNA准入计划框架下合作开发汉坦病毒mRNA疫苗。这一利好消息带动了整个疫苗板块的上涨。作为疫苗板块的重要成员，诺瓦瓦克斯医药的股价也受到板块联动效应的影响而大幅上涨。同期，莫德纳股价盘前上涨9%，Inovio股价上涨11%，防护服制造商莱克兰工业和阿尔法普罗科技的股价也均上涨约6%，显示出市场对生物技术板块的积极情绪。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162351313","title":"异动解读 | 诺瓦瓦克斯医药盘中大涨17.96%，因第一季度营收远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1162351313","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162351313?lang=zh_cn&edition=full","pubTime":"2026-05-07 01:26","pubTimestamp":1778088408,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）今日盘中股价大幅上涨17.96%，引起了市场的广泛关注。消息面上，该公司公布的第一季度营收表现强劲，超出了华尔街分析师的普遍预期。根据报告，诺瓦瓦克斯第一季度营收达到1.395亿美元，远高于分析师平均预期的7830万美元，这主要得益于疫苗供应及授权协议带来的预付款和里程碑付款，有效抵消了市场需求疲软带来的压力。此外，公司管理层表示正持续推进降本增效计划，目标是在未来几年内大幅削减研发及行政费用，并维持了2026年的调整后营收预测。这些积极的财务表现和成本控制措施增强了投资者对公司未来发展的信心，推动了股价的显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140535232","title":"异动解读 | 股东敦促资本管理，诺瓦瓦克斯医药盘前大涨7.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140535232","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140535232?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:39","pubTimestamp":1775644766,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药今日盘前大涨7.64%，引起了市场的广泛关注。消息面上，知名投资机构Shah Capital公开呼吁诺瓦瓦克斯医药采取积极资本管理措施，建议其尽快赎回2.25亿美元可转换债券，并考虑启动1000万至2000万股的股票回购计划。这一举措被市场解读为股东对提升公司估值的最新努力，通过优化资本结构、降低财务杠杆和传递股价被低估的信号，从而可能引发投资者积极反应。诺瓦瓦克斯医药作为疫苗研发领域的重要参与者，其资本运作动向备受关注。投资者正密切关注公司管理层是否会响应这一股东提案，以及后续可能采取的具体实施方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138462511","title":"诺瓦瓦克斯医药盘前股价飙升6.1%；维权投资者Shah Capital宣布将投票反对公司高管薪酬及董事提名","url":"https://stock-news.laohu8.com/highlight/detail?id=1138462511","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138462511?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:07","pubTimestamp":1775642839,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）股价在盘前交易时段大幅上涨6.1%，引发市场关注。与此同时，知名维权投资机构Shah Capital公开表示，将在公司即将举行的股东大会上对高管薪酬方案及董事会候选人名单投下反对票。\n这一股价异动与股东积极行动同时出现，凸显了市场对诺瓦瓦克斯医药公司治理状况的高度关注。Shah Capital作为长期关注公司治理的活跃投资者，此次采取反对立场可能影响其他机构投资者的投票决策。\n目前，诺瓦瓦克斯医药尚未就此事发表官方评论。市场分析师指出，此类股东行动通常反映了投资者对公司战略方向或管理层表现的不满，可能促使公司重新评估其治理结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVAX","BK4139","BK4568","BK4547","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novavax.com","stockEarnings":[{"period":"1week","weight":0.1904},{"period":"1month","weight":0.2654},{"period":"3month","weight":-0.1488},{"period":"6month","weight":-0.1564},{"period":"1year","weight":0.2553},{"period":"ytd","weight":0.4048}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novavax, Inc.于1987年根据美国特拉华州法律注册成立，是一家临床阶段的生物制药公司，专注于重组纳米颗粒疫苗和佐剂的发现、开发和商业化。该公司的疫苗技术平台基于包括病毒样颗粒（VLP）和蛋白质纳米颗粒候选疫苗的专有重组纳米颗粒疫苗技术。该公司的候选疫苗是基因工程的三维纳米结构，其中包含了免疫学上重要的蛋白质。公司的疫苗产品管线针对多种传染病，候选药物目前处于呼吸道合胞病毒（RSV）、季节性流感、大流行性流感的临床开发阶段。此外，该公司在印度的合资公司CPL Biologics Private Limited（CPLB）正在积极开发多款候选疫苗，这些候选疫苗由诺瓦瓦克斯医药进行基因工程改造。","yearOnYearQuotes":[{"month":1,"riseRate":0.677419,"avgChangeRate":0.108114},{"month":2,"riseRate":0.580645,"avgChangeRate":0.042802},{"month":3,"riseRate":0.258065,"avgChangeRate":-0.045948},{"month":4,"riseRate":0.451613,"avgChangeRate":0.007887},{"month":5,"riseRate":0.548387,"avgChangeRate":0.134336},{"month":6,"riseRate":0.483871,"avgChangeRate":0.082895},{"month":7,"riseRate":0.548387,"avgChangeRate":0.011604},{"month":8,"riseRate":0.548387,"avgChangeRate":0.047941},{"month":9,"riseRate":0.5,"avgChangeRate":-0.036425},{"month":10,"riseRate":0.3,"avgChangeRate":0.027361},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.003351},{"month":12,"riseRate":0.366667,"avgChangeRate":-0.038609}],"exchange":"NASDAQ","name":"诺瓦瓦克斯医药","nameEN":"Novavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺瓦瓦克斯医药,NVAX,诺瓦瓦克斯医药股票,诺瓦瓦克斯医药股票老虎,诺瓦瓦克斯医药股票老虎国际,诺瓦瓦克斯医药行情,诺瓦瓦克斯医药股票行情,诺瓦瓦克斯医药股价,诺瓦瓦克斯医药股市,诺瓦瓦克斯医药股票价格,诺瓦瓦克斯医药股票交易,诺瓦瓦克斯医药股票购买,诺瓦瓦克斯医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}